注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗36例风湿免疫疾病患者的临床疗效研究

Study on Clinical Effect of Recombinant Human Tumor Necrosis Factor-αReceptor Ⅱ : Ig G Fc Fusion Protein for Injection in the Treatment of 36 Cases of Patients With Rheumatic Diseases

目的评价风湿免疫疾病患者采取注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗的临床疗效。方法将72例确诊为类风湿关节炎的患者作为研究的对象,随机分为两组;对照组采取常规方法治疗,观察组在常规方法治疗的基础上采取注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗,对比两组患者临床疗效及不良反应发生情况。结果观察组中治疗反应良好21例(58.33%)、治疗反应一般10例(27.78%),无治疗无反应5例(13.89%)。对照组3中治疗反应良好8例(22.22%)、治疗反应一般12例(33.33%),治疗无反应16例(44.44%)。两组数据差异有统计学意义(P<0.05),两组在不良反应发生率方面差异无统计学意义(P>0.05)。结论类风湿关节炎患者采取注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗效果显著。

Objective Clinical efficacy of recombinant human tumor necrosis factor-αreceptor Ⅱ ： Ig G Fc fusion protein for injection in the treatment of patients with rheumatic disease is evaluated. Methods 72 cases of rheumatoid arthritis patients were taken as the research object, the control group was treated with conventional methods, the observation group was treated with recombinant human tumor necrosis factor-αreceptor Ⅱ ： Ig G Fc fusion protein for injection. Results In the observation group, 21 cases（58.33%） had good response, 10 cases had response（27.78%）, 5 cases had no response（13.89%）. In control group, there were 3 cases（22.22%）, 8 cases（33.33%）, 12 cases（44.44%） respectively. The difference between the two groups was statistically significant（P〈0. 05）, and there was no significant difference between the two groups in the incidence of adverse reactions（P〈0. 05）. Conclusion Effect of patients with rheumatoid arthritis by recombinant human tumor necrosis factor-αreceptor Ⅱ ： Ig G Fc fusion protein for injection is significant.